{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:27Z","timestamp":1794270147259,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["861323"],"award-info":[{"award-number":["861323"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-00657"],"award-info":[{"award-number":["2022-00657"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107946","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:17:10Z","timestamp":1785338230000},"page":"107946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An exploratory pharmacokinetic\/pharmacodynamic analysis of ceftazidime-avibactam and various blood biomarkers in patients with hospital-acquired pneumonia or ventilator-associated pneumonia caused by Klebsiella pneumoniae"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6217-4283","authenticated-orcid":false,"given":"Amaury","family":"O\u2019Jeanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-214X","authenticated-orcid":false,"given":"Elisabet I.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-879X","authenticated-orcid":false,"given":"Zoe","family":"Athanassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5546-6099","authenticated-orcid":false,"given":"Aghavni","family":"Ginosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-8066","authenticated-orcid":false,"given":"Konstantinos","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Manioudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-5065","authenticated-orcid":false,"given":"Helen","family":"Giamarellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosif","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-2190","authenticated-orcid":false,"given":"Nikoletta","family":"Skarmoutsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Mylona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3199-9158","authenticated-orcid":false,"given":"Aikaterini","family":"Sakagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-4416","authenticated-orcid":false,"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0239","authenticated-orcid":false,"given":"Ilias","family":"Karaiskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107946_bib0001","series-title":"Zavicefta 2g\/0.5g (ceftazidime\/avibactam) powder for solution for infusion","year":"2021"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0002","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.clinthera.2020.03.014","article-title":"Cost-effectiveness comparison of Ceftazidime\/Avibactam versus Meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy","volume":"42","author":"Tichy","year":"2020","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.37201\/req\/s03.06.2022","article-title":"Current treatment of nosocomial pneumonia and ventilator-associated pneumonia","volume":"35","author":"Plata-Menchaca","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0004","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","article-title":"Towards precision medicine: therapeutic drug monitoring\u2013guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the Therapeutic range","volume":"44","author":"Abdul\u2013Aziz","year":"2022","journal-title":"Therapeut Drug Monitor"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0006","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.21037\/jtd.2020.01.47","article-title":"An approach to antibiotic treatment in patients with sepsis","volume":"12","author":"Mart\u00ednez","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0008","doi-asserted-by":"crossref","unstructured":"Aulin LBS, Lange DW de, Saleh MAA, van der Graaf PH, V\u00f6ller S, van Hasselt JGC. Biomarker-guided individualization of antibiotic therapy. Clin Pharmacol Therapeut. https:\/\/doi.org\/10.1002\/cpt.2194.","DOI":"10.1002\/cpt.2194"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime-Avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0011","article-title":"Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)","volume":"65","author":"O\u2019Jeanson","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0012","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, version 15.0. 2025. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf. Accessed October 30, 2025."},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0013","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Ceftazidime-avibactam: Rationale for the clinical breakpoints, version 1.0. 2020. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Ceftazidime-avibactam_Rationale_Document_20200730.pdf. Accessed October 30, 2025."},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0014","first-page":"S84","article-title":"Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve","volume":"42","author":"Baron","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cmpb.2012.05.005","article-title":"PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool","volume":"108","author":"Nyberg","year":"2012","journal-title":"Comput Meth Prog Biomed"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/sur.2018.141","article-title":"Pharmacokinetic and pharmacodynamic analysis of Ceftazidime\/Avibactam in critically ill patients","volume":"20","author":"Stein","year":"2018","journal-title":"Surg Infect"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcph.1510","article-title":"Monte Carlo simulation methodologies for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: effect on probability of target attainment assessments","volume":"60","author":"Kidd","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkae375","article-title":"Therapeutic drug monitoring (TDM) of \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) drug combinations: insights from a pharmacometric simulation study","volume":"80","author":"O\u2019Jeanson","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0019","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00134-022-06956-y","article-title":"How to use biomarkers of infection or sepsis at the bedside: guide to clinicians","volume":"49","author":"P\u00f3voa","year":"2023","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0021","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0736-4679(99)00135-3","article-title":"The C-reactive protein1","volume":"17","author":"Clyne","year":"1999","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0022","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1172\/JCI116336","article-title":"Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease","volume":"91","author":"Vigushin","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0023","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/1354750X.2011.607189","article-title":"Kinetics of c-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times","volume":"16","author":"Takata","year":"2011","journal-title":"Biomarkers"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0024","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bcp.13477","article-title":"The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling","volume":"84","author":"Netterberg","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0885066610395678","article-title":"Interleukin-6 in surgery, trauma, and critical care: part I: basic science","volume":"26","author":"Jawa","year":"2011","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0885066610384188","article-title":"Interleukin-6 in surgery, trauma, and critical care part II: clinical implications","volume":"26","author":"Jawa","year":"2011","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0027","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease\u2013Drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002640000136","article-title":"Interleukin-6: a potential inflammatory marker after total joint replacement","volume":"24","author":"Wirtz","year":"2000","journal-title":"Int Orthop"},{"key":"10.1016\/j.ijantimicag.2026.107946_bib0029","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cpt.2182","article-title":"Pivotal role of translation in anti-infective development","volume":"109","author":"Friberg","year":"2021","journal-title":"Clin Pharmacol Therapeut"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:38:41Z","timestamp":1794267521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002335"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107946","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An exploratory pharmacokinetic\/pharmacodynamic analysis of ceftazidime-avibactam and various blood biomarkers in patients with hospital-acquired pneumonia or ventilator-associated pneumonia caused by Klebsiella pneumoniae","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107946"}}